Novel Approaches to Drug Development in Oncology and Immune Diseases




Recorded August 18, 2015

 

Sponsored by
Nodality logo  

Webinar Description:

Drug developers have a substantial opportunity before them to revolutionize patient care and the development of precision therapeutics. A hurdle to realizing the full value of novel therapies is finding better translational models capable of capturing heterogeneity across patients, the complexities of disease pathobiology and to identify and evaluate drug activity and drug combinations in a cognate model in advance of running extensive, expensive clinical trials. The webinar is a discussion on market opportunities, specific applications and potential solutions to some of the challenges of more efficiently and effectively developing therapeutics.

Learning Objectives:

  • Industry opportunity to improve patient care and clinical development
  • Challenges facing developers of novel therapeutics
  • Current technological approaches and strategies to interrogate drug activity and select biomarkers
  • Benefits and limitations of current approaches to drug development
  • Value of Functional Proteomics to optimize the impact and effectiveness of novel therapeutics

Speakers:

Dr. Rachael Hawtin, Ph.D.

VP Research

Nodality

Dr. Rachael Hawtin has over 17 years of experience in drug development, encompassing small molecules and biologics for oncology and autoimmune indications. She has held leadership positions in drug development programs spanning discovery biology through to clinical development in the context of both international companies and small biotechnology organizations. Prior to joining Nodality, she held various positions at Sunesis Pharmaceuticals, progressing to the lead role in the translational science component of two clinical stage programs. Rachael previously led the small molecule target discovery program at Chiron Corporation. Additionally, she held progressively responsible positions at Sugen Inc., where she served as leader of a protein expression technology group, and as leader of a small molecule oncology drug development program. Rachael completed her B.Sc. at the University of Edinburgh, Scotland, and her Ph.D. at the Institute of Virology and Environmental Microbiology (IVEM) in Oxford, England.

Dr. Santosh Putta, Ph.D.

VP, Computational Sciences

Nodality

Dr. Santosh Putta has over 15 years of experience in creating software and data solutions in the life sciences industry. Prior to Nodality, he was involved in designing and implementing several computational algorithms, machine learning methods, and software solutions in the drug design space, including co-authoring an open source cheminformatics and machine learning toolkit. At Nodality he has been responsible for establishing the software and data analysis infrastructure, in addition to leading statistical analysis and design on multiple clinical studies. He holds a Bachelor of Technology degree in Mechanical Engineering from the Indian Institute of Technology, Chennai and a Ph.D. in Materials Science from the University of California, San Diego.

Dr. Bradford A. Young, Ph.D., MBA

VP, Business Development

Nodality

Dr. Bradford A. Young is an accomplished life sciences executive with over 20 years of experience developing markets, designing and launching innovative products, creating strategic partnerships and leading commercial programs. His deep business and technical background has enabled him to successfully capitalize on unmet medical needs and market opportunities. As Head of Business Development, Dr. Young is leading Nodality’s sales and marketing efforts. Dr. Young’s leadership experience prior to Nodality included CEO of the life sciences start-up company AddisonField, Executive Director of the SFY Foundation, a cancer charity and Director of Market and Business Development for Quest Diagnostics (formerly Celera). Dr. Young is also actively involved in the industry as a mentor for the LeanLaunch Pad, a NSF I-Corps™ program and as a selection committee member for SPADA, the Stanford Predictives and Diagnostics Accelerator program. Dr. Young earned his doctorate from the University of Maryland, School of Medicine and his MBA from the University of California, Berkeley, Haas School of Business.


Cost: No cost!

Schedule conflict? Register and you'll receive a copy of the recording!

Download Webinar


By Series:
By Region: